The Medicines Co. (NASDAQ:MDCO)’s share price traded up 3.9% on Thursday . The company traded as high as $38.37 and last traded at $38.33, with a volume of 448,505 shares trading hands. The stock had previously closed at $36.90.

A number of equities analysts have weighed in on the company. Zacks Investment Research upgraded The Medicines from a “sell” rating to a “hold” rating in a research note on Monday, August 1st. Citigroup Inc. reiterated a “hold” rating on shares of The Medicines in a research note on Tuesday, August 2nd. Cowen and Company reiterated a “buy” rating and set a $45.00 price objective on shares of The Medicines in a research note on Friday, August 5th. Chardan Capital reiterated a “buy” rating on shares of The Medicines in a research note on Thursday, June 2nd. Finally, Guggenheim reiterated a “buy” rating and set a $55.00 price objective on shares of The Medicines in a research note on Monday. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The Medicines presently has a consensus rating of “Buy” and an average price target of $47.33.

The stock’s market cap is $2.64 billion. The stock has a 50 day moving average of $36.41 and a 200-day moving average of $34.58.

The Medicines (NASDAQ:MDCO) last released its quarterly earnings data on Wednesday, July 27th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.54. During the same quarter in the prior year, the company earned ($0.65) EPS. The company earned $54.70 million during the quarter, compared to analyst estimates of $41.93 million. The business’s revenue was down 26.5% on a year-over-year basis. On average, equities analysts anticipate that The Medicines Co. will post ($1.36) earnings per share for the current year.

In related news, EVP Christopher T. Cox acquired 53,340 shares of the firm’s stock in a transaction on Tuesday, June 7th. The stock was bought at an average price of $37.55 per share, for a total transaction of $2,002,917.00. Following the completion of the purchase, the executive vice president now directly owns 20,800 shares of the company’s stock, valued at approximately $781,040. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Melvin K. Spigelman sold 15,000 shares of the company’s stock in a transaction on Tuesday, May 24th. The shares were sold at an average price of $37.00, for a total transaction of $555,000.00. Following the completion of the transaction, the director now owns 53,970 shares of the company’s stock, valued at approximately $1,996,890. The disclosure for this sale can be found here.

A number of institutional investors recently added to or reduced their stakes in MDCO. First Trust Advisors LP bought a new position in The Medicines during the fourth quarter valued at about $1,715,000. New York State Common Retirement Fund boosted its stake in shares of The Medicines by 13.2% in the fourth quarter. New York State Common Retirement Fund now owns 70,394 shares of the company’s stock worth $2,629,000 after buying an additional 8,194 shares during the last quarter. Mutual of America Capital Management LLC boosted its stake in shares of The Medicines by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 45,349 shares of the company’s stock worth $1,693,000 after buying an additional 270 shares during the last quarter. Bank of Montreal Can boosted its stake in shares of The Medicines by 29.4% in the fourth quarter. Bank of Montreal Can now owns 297,492 shares of the company’s stock worth $11,108,000 after buying an additional 67,616 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of The Medicines by 8.5% in the fourth quarter. Principal Financial Group Inc. now owns 468,857 shares of the company’s stock worth $17,507,000 after buying an additional 36,761 shares during the last quarter.

The Medicines Company is a global biopharmaceutical company. The Company’s marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.